BioCentury
ARTICLE | Company News

Pfizer, XRpro deal

August 10, 2015 7:00 AM UTC

XRpro acquired from Pfizer assets related to the ion channel biology platform the pharma obtained in its 2011 acquisition of Icagen Inc. The purchase includes Pfizer’s rights to the “Icagen” name and trademark. XRpro relaunched as Icagen Inc. to provide ion channel and transporter drug discovery services. Pfizer scientists associated with the ion channel biology platform will transition to the new Icagen. ...